Enovis (ENOV) Stock Price

Enovis Price

NYSE·CLOSED
17.61
​
Market closed

Revenue has compounded at 9.6% per year over the past 19 years to 2.25 B USD. Earnings per share have grown at 34.7% per year over the last 15 years. Enovis's net margin stands at -52.7%, down from 5.0% several years earlier. Analysts set a median price target of 45.00 USD, implying 155.5% above the current price. Of 19 analysts, 17 rate the stock a buy — an overall Buy consensus.

Enovis stock price

Access this data via the Eulerpool API

Enovis business model & stock analysis

Enovis Corp. operates as a medical technology growth company. The company is headquartered in Wilmington, Delaware and currently employs 6,800 full-time employees. The company went IPO on 2008-05-08. The company is focused on developing clinically differentiated solutions by manufacturing and distributing medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. The company operates in two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment develops, manufactures, and distributes rigid bracing products, orthopedic soft goods, vascular systems and compression garments, and hot and cold therapy products and offers recovery sciences products in the clinical rehabilitation and sports medicine markets, such as bone growth stimulators and electrical stimulators used for pain management. The Reconstructive segment develops, manufactures, and markets a variety of knee, hip, shoulder, elbow, foot, ankle, and finger implant products and surgical productivity solutions. The company also provides Novastep, a minimally invasive surgery (MIS) foot and ankle solutions.

Frequently asked questions about Enovis

Analysts currently set an average price target of 42.00 USD for the Enovis stock (median: 45.00 USD), implying +138.5 % versus the latest price. The consensus is based on 19 analyst ratings.

19 analysts currently rate the Enovis stock: 17 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Enovis to generate revenue of 2.34 B USD and earnings per share of 3.66 USD.

Converted at the current exchange rate, the Enovis share trades at 15.71 EUR (17.61 USD).

The Enovis share (ENOV) is listed on 3 stock exchanges, including: NYSE (ENOV), London (0I1B.L), München (C520.MU).

The expected revenue of Enovis is 2.34 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Enovis is 208.14 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Enovis is currently 4.81. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Enovis stock.

The price-to-sales ratio (P/S) of Enovis is currently 0.43. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Enovis stock.

The Eulerpool Quality Score for Enovis is 2/10.

The ISIN of Enovis is US1940145022. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Enovis is A3DHHV. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Enovis is ENOV. The ticker symbol is used to trade Enovis shares on the stock exchange.

Fair ValueTerminal
17.08 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue per Employee
288,137.53 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website enovis.com
Currency
USD
Initial public offering
May 8, 2008
ISIN
US1940145022
Cusip
194014502
Market capitalization
1.01 B USDSmall Cap
52-Week Range
PEG
-0.14
P/E ratio
P/Ee 2026
4.84
P/Ee 2027
4.77
P/Ee 2028
4.36
P/Ee 2029
3.81
P/S
P/Se
0.43
EV/EBIT
—
P/B Ratio
0.68
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-42.13 %
Last updated Oct 9, 2026, 4:14 AM

Enovis Peer Group

Enovis Ticker

LONDON · 0I1B.LMUNICH · C520.MUNEW YORK · ENOV

Enovis FIGI

ENOV:US · BBG000C5Z443ENOV:UA · BBG000C5Z4C4ENOV:UC · BBG000C5Z4R8ENOV:UN · BBG000C606W3ENOV:UP · BBG000C60760ENOV:UB · BBG000C607X0ENOV:UT · BBG000C608B2ENOV:UM · BBG000C609G5ENOV:UX · BBG000C609X6ENOV:UD · BBG000C60D94ENOV:UF · BBG000C60GG9ENOV:VY · BBG000C60GX0

All fundamentals and in-depth analysis of Enovis

Our stock analysis for Enovis stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Enovis. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.